Identification of the antigens predominantly reacted with serum from patients with hepatocellular carcinoma

Abstract

BACKGROUNDTo identify antigens specifically recognized by the immune surveillance system in patients with hepatocellular carcinoma (HCC), the authors examined two complementary DNA (cDNA) libraries of moderately differentiated HCC by serologic analysis of recombinant cDNA expression libraries (SEREX).METHODSThe libraries were screened with autologous patients' sera, and sequences of the reacted clones were determined. To study the immunoreactivity of the antigens, sera from 20 patients with HCC, from 20 healthy volunteers, and from 16 patients with chronic viral hepatitis were examined.RESULTSTwenty‐seven antigens were identified. They included SART1, p57Kip2, ROCK‐1, γ‐catenin, and heat shock proteins, which are classified as tumor‐associated genes. Three of 27 antigens—Tat‐binding protein‐1 (TBP‐1), β4 integrin‐binding protein (p27[BBP]), and ribosomal protein L30 (rpL30)—were reacted predominantly with sera from patients with HCC (55% of patients, 45% of patients, and 20% of patients, respectively). Patients in the control group had no antibodies against these three antigens. Seventy percent of patients with HCC had the antibody against at least one of these antigens.CONCLUSIONSDisease specific humoral immune response against TBP‐1, p27(BBP), and rpL30 was induced in patients with HCC, and the antibodies against these antigens also may be used as tumor markers. Cancer 2003;97:2474–9. © 2003 American Cancer Society.DOI 10.1002/cncr.11374

Identification and analysis of tumour-associated antigens in hepatocellular carcinoma

“…Of these, one is CT antigen (CAGE), which was first reported to be expressed in gastric cancer by Cho et al (2002) and found to be hypomethylated in the majority specimens of human HCC (Cho et al, 2003). Intriguingly, none of the 30 antigens overlapped with the antigens detected by the other two groups (Stenner-Liewen et al, 2000;Uemura et al, 2003), and only one of them (HCA58) was identified in our previous report . Knowledge in the immunogenicity and expression pattern of serologically defined tumour antigens is critical in assessing their relevance to cancer and their therapeutic and diagnostic potentials.…”

“…Given that the size of the SEREX-defined cancer immunome, the repertoire of tumour antigens capable of eliciting immune response in cancer patients, is estimated to have 4000 antigens, continued efforts in SEREX screening should extend our understanding of tumour antigens (Lee et al, 2004b). With the aim to identify potent tumour-associated antigens for clinical applications, the SEREX screening of HCC cDNA expression library was performed in several laboratories (Stenner-Liewen et al, 2000;Uemura et al, 2003). These findings imply that different tumourassociated antigens may be identified by SEREX from distinct HCC samples.…”

Identification of Novel SNPs in Glioblastoma Using Targeted Resequencing

“…The SNP rs660118 maps within the SART1 (squamous cell carcinoma antigen recognized by T cells) gene that is also known as tumor-rejection antigen in brain tumors [28] and in a range of other tumors including hepatocellular carcinoma [29], colorectal cancer [30], renal cell carcinoma [31], and osteosarcoma [32]. Amplification and overexpression of SART1 occurs in head and neck squamous cell carcinoma (HNSCC) [33].…”

A microarray method for identifying tumor antigens by screening a tumor cDNA expression library against cancer sera

“…An analysis of these proteins reveals that there are many different categories of non-normal proteins recognized by the immune system of a tumor-bearing host. Well-studied tumor antigens include cancer testis (CT) antigens, heat shock proteins, 17 and oncoproteins such as HER-2/Neu and p53. These have been identified as normal cell antigens that are overexpressed in tumor cells 18 .…”